Physician profile
Frederick Reindel
NPI 1134117492
$2,143.18
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $298 · 2021: $764 · 2022: $528 · 2023: $95.12 · 2024: $27.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $122.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $320.85 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $273.75 | 2019-2022 | |
| Abbvie INC. | $199.00 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $190.27 | 2020-2023 | |
| Neurocrine Biosciences, INC. | $177.73 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $159.53 | 2019-2024 | Trintellix |
| Alkermes, INC. | $148.00 | 2020-2023 | Aristada, Lybalvi |
| Jazz Pharmaceuticals INC. | $95.00 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $91.92 | 2019-2023 | Fanapt |
| Allergan, INC. | $84.59 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $67.58 | 2019-2021 | |
| Lundbeck LLC | $58.85 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $51.56 | 2022-2023 | Qelbree |
| Neuronetics, INC. | $46.52 | 2019 | |
| Orexo US, INC. | $46.20 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $37.44 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $31.10 | 2021 | |
| Avanir Pharmaceuticals, INC. | $29.44 | 2019 | |
| Acadia Pharmaceuticals INC | $21.85 | 2022 | |
| Corium, LLC | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Reindel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.